Here’s which ion channels are routinley screened in the pharma industry (Authier et al., 2017):
NaV1.5 is cardiac sodium channel, CaV1.2 is cardiac “L-type” calcium channel, kvLQT1 is cardiac lks current
Refine your decision making with a deeper understanding of the potential for effects on cardiac safety to deliver an optimal and de-risked clinical candidate. ApconiX routinely offer sodium and calcium channel assays for a more comprehensive assessment of cardiac liability. On a case-by-case basis we can also deploy other cardiac ion channel assays to suit your needs including cardiac ‘T-type’ calcium channels and Kv1.5 as well as more advanced models of cardiac safety such as Purkinje fibre, cardiac contractility and Langendorf models.
It is a regulatory requirement that an assessment of hERG inhibition should be made by manual patch-clamp to Good Laboratory Practise (GLP) standards. GLP-hERG is provided through our expert partners.
Given over 500 years of combined expertise in drug discovery and safety, ApconiX is uniquely positioned to work with your project team to
interpret your data in the context of your drug discovery program.